FDA U.S. FOOD & DRUG ADMINISTRATION

The Honorable Andy Harris, M.D.
House of Representatives
1533 Longworth House Office Building
Washington, DC 20515

FEB 06 2019

Dear Congressman Harris:

Thank you for your letter dated October 15, 2018, to the U.S. Food and Drug Admininistration (FDA) regarding MedWatch reports of patients discontinuing their anticoagulants, antidepressants, and antidiabetic therapies after viewing a legal advertisement.

In your letter, you requested that the Agency pull various types of MedWatch summary reports in the FDA Adverse Event Reporting System (FAERS) database that FDA received concerning patients who discontinued their anticoagulants, antidepressants, and antidiabetic products after viewing a legal advertisement.

In performing the searches you requested, FDA identified 213 reports in which a patient viewed an advertisement and then discontinued their antidiabetic, antidepressant, or anticoagulant medication.

- Approximately 21% (44/213) of all reports described patients viewing a legal advertisement and then discontinuing their medication.
- 14 report narratives mentioned "Bad drug ads" as the advertisement that prompted medication discontinuation.
- In 73% (155/213) of the reports that described medication discontinuation after viewing an advertisement, we were unable to determine the specific type of advertisement.
- Approximately 27% (58/213) of all reports described an adverse event after medication discontinuation.
- Reports of medication discontinuation after viewing an advertisement were submitted from 37 different states.

Furthermore, attached you will find specifc details of the queries the Agency performed to ensure you have a full understanding of the methodology of reviewing the MedWatch reports and our findings. An explanation of the limitations of this review is also included in Appendix A.

Thank you for contacting us concerning this matter. Please let us know if you have further questions.

Sincerely,

Maren McBride
Legislative Director for Appropriations

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

ATTACHMENT 1.

METHODS AND MATERIALS

The FAERS search criteria is described in **Table 1**.

Table 1. FAERS Search Strategy*

Date of search	October 22, 2018
Time period of search	All reports through September 30, 2018
Products	Anticoagulants, antidepressants, antidiabetic agents†
Country	United States
Other Search Criteria‡	Narrative search: ("adverti" [OR] "tv" [OR] "televis" [OR] "commercial" [OR] "publicity" [OR] "bad drug") [AND] ("discontin" [OR] "not taking" [OR] "stop" [OR] "quit")

* See **Appendix B** for a description of the FAERS database.
† See **Appendix C** for all product active ingredients.
‡ Text strings were case insensitive.

Identification of reports was an iterative process that required multiple preliminary searches. In response to your first inquiry in 2016, the Division of Pharmacovigilance (DPV) conducted preliminary searches in the FAERS database using the list of terms provided in your inquiry. We excluded several terms from the current search because these yielded a large number of reports unrelated to medication discontinuation following viewing legal advertisements. For example:

- Lawyer/attorney: a disproportionate number of litigation reports have been submitted to FDA that are unrelated to medication discontinuation because of a legal advertisement
- Radio: non-specific because of the frequency of references to unrelated terms such as radiographs, radiology, and estradiol
- Ad: non-specific because "ad" is a common component of words such as addition
- Contact/call: non-specific and non-informative in identifying related reports to the topic of the search

Because expanded search capabilities using logic and Boolean terms are not available in FAERS Business Intelligence Solution (FBIS), DPV searched the FAERS using Empirica Signal 7.3. Partial words were used in the narrative search to allow for variation of the words by reporters (e.g., misspelling, plural forms).

In our final search for the first inquiry in 2016, we included an additional term, "bad drug," because many reports contain this specific descriptor when referring to the viewed drug advertisements. We applied the query identified in Empirica Signal as having the highest utility to the FAERS data retrieved from FBIS for validation. Statistical Analysis System (SAS) software was used to apply the narrative criteria to the data retrieved from FBIS (SAS Institute Inc., version 9.4, Cary, NC).

For the current inquiry, our strategy for retrieving reports followed the same rationale, with one modification: we focused our search on identification of "drug discontinuation" instead of "drug

discontinuation *or* dose tapering." This decision was made after consideration of the volume of reports retrieved and reviewed for the first inquiry, the subsequent low yield of a single report of decreased dose, and the large volume of reports retrieved across all anticoagulants, antidiabetic agents, and antidepressants for the present inquiry.

Below is a summary of all reports describing discontinuation of an anticoagulant, antidiabetic, or antidepressant agent after viewing an advertisement through September 30, 2018. This includes reports of Novel Oral Anticoagulant (NOAC) discontinuation identified from the 2016 inquiry.

REPORT SELECTION CRITERIA

We included FAERS reports if:

- Patient was taking an anticoagulant, antidepressant, or antidiabetic product AND
- Patient reportedly discontinued therapy after viewing an advertisement

We characterized reports meeting the above criteria by product, patient demographics, advertisement type, advertisement medium, adverse events reported following drug discontinuation if any, reporter state, reporter qualification (i.e., consumer, healthcare provider, lawyer), and FDA initial received date.

We classified the advertisement type into three categories based on the description in the narrative:

- "Legal" advertisements clearly described a lawyer or law firm advertisement or appeared to be advertisements that advise consumers to contact a law firm for help
- "Bad drug" advertisements described "Bad drug ads" in the report narrative. These ads appear to be public service announcements describing side effects of a product. The source of the advertisement was unclear (e.g., lawyers, law firm, advocacy group).
- "Unspecified" advertisements did not provide enough information to classify the advertisement (e.g., "I saw an advertisement on TV and decided to discontinue the drug X.")

RESULTS

The FAERS search retrieved 2,865 reports. After applying the report selection criteria listed above, we identified 213 reports where patients presumably saw an advertisement that prompted medication discontinuation. **Table 2** summarizes the descriptive characteristics. **Appendix D** lists the FAERS report numbers, FAERS version numbers, and Manufacturer Control numbers for the 213 reports. Note that all of these characteristics are based solely upon the information provided by the reporter to FDA; FDA has not independently verified its accuracy.

Table 2. Descriptive Characteristics of FAERS Reports of Antidiabetic, Antidepressant, and Anticoagulant Discontinuation after Viewing an Advertisement, Received by FDA Through September 30, 2018 (n=213 reports)

	Antidiabetics (n=108)	**Antidepressants¶ (n=36)**	**Anticoagulants* (n=69)**
Age (years)†	n=68	n=21	n=29
Mean	62	54	81
Median	62	55	81
Range	44-86	14-91	76-90
Sex			
Male	45	8	31
Female	59	28	27
Not reported	4	-	11
Discontinued medication	Canagliflozin (21) Canagliflozin/metformin (1) Dapagliflozin (2) Empagliflozin (1) Exenatide (4) Glimepiride/rosiglitazone (2) Insulin glargine (1) Liraglutide (4) Metformin/rosiglitazone(4) Metformin/sitagliptin (1) Pioglitazone (4) Rosiglitazone(39) Saxagliptin (1) Sitagliptin (21) Troglitazone§ (2)	Aripiprazole (9) Brexpiprazole (1) Duloxetine (16) Lurasidone (2) Olanzapine (1) Paroxetine (1) Quetiapine (5) Risperidone (1)	Apixaban (4) Rivaroxaban (57) Dabigatran (8)
Reporter qualification			
Heath care professional	36	4	50
Consumer	48	25	19
Lawyer‖	23	1	-
Not reported	1	6	-
Advertisement type			
Legal	17	2	25
Bad drug	2	-	12
Unspecified	89	34	32
Advertisement medium			
TV	66	34	41
Other∞	2	-	1
Unknown€	40	2	27
Reported subsequent adverse event	n=6 Hyperglycemia (3) Elevated A1c (2) Weight gain (1)	n=6 Headache (2) Hospitalization (1) Suicide (1) Depression (1) Withdrawal Symptoms (1)	n=46 Stroke‡ (32) Transient Ischemic Attack (2) Thromboembolism‡,£ (11) Unspecified¥ (1)
Year report initially received by FDA	1997 (1) 1998 (1) 2001 (1) 2003 (1) 2004 (2)	2001 (1) 2004 (1) 2006 (1) 2007 (1) 2010 (4)	2012 (4) 2013 (2) 2014 (8) 2015 (33) 2016 (13)

	2007 (3) 2008 (4) 2009 (10) 2010 (4) 2011 (8) 2012 (18) 2013 (13) 2014 (11) 2015 (10) 2016 (10) 2017 (3) 2018 (8)	2011 (2) 2012 (3) 2013 (1) 2014 (2) 2015 (10) 2016 (4) 2017 (4) 2018 (2)	2017 (6) 2018 (3)

*Includes NOAC discontinuation reports previously identified in the prior 2016 Congressional request
† Refers to the number of reports in which the specific demographic data were provided; balance of the total had incomplete data
§ Troglitazone was withdrawn from the US market in 2000
‖ Among the 23 lawyer reports for the antidiabetics, there were multiple firms, lawyers, and states represented.
∞Includes all other advertisement medium (e.g., print, radio)
€ Unknown refers to reports where the advertisement medium was not specified
‡ Includes six death reports after either a stroke or thromboembolism
£Thromboembolic events include pulmonary embolism, deep vein thrombosis, splenic infarct, and "clots"
¥ Report of death but adverse event was not specified
¶List includes atypical antipsychotics with indications for major depressive disorder or depressive episodes associated with bipolar disorder.

Table 3. A List of Reporters' Home States for Reports of Antidiabetic, Antidepressant, and Anticoagulant Discontinuation after Viewing an Advertisement, Received by FDA Through September 30, 2018 (n=179*) (as reported, not verified by FDA)

	Antidiabetics (n=89)	**Antidepressants (n=29)**	**Anticoagulants† (n=61)**	**Total number of reports by state**
Reporter State	AK (1) AL (4) AR (2) AZ (1) CA (7) CT (3) FL (6) GA (3) IL (2) IN (3) KY (2) LA (3) MA (1) MD (3) MI (2) MO (3) MS (2) NC (3) NM (2) NY (9) OH (5) PA (5) TN (3)	CA (4) GA (1) KY (1) MA (2) MI (3) MN (1) MO (1) NC (1) NE (1) NJ (2) NM (1) NV (1) NY (2) OH (1) PA (1) SC (1) TX (4) VA (1)	CA (1) CO (2) CT (5) DE (3) FL (10) GA (3) IL (1) IN (1) KS (1) KY (2) LA (4) MA (2) MD (1) MI (3) MO (2) MS (1) NC (2) NE (1) NV (1) NY (3) OH (2) OK (1) RI (1)	AK (1) AL (4) AR (2) AZ (1) CA (12) CO (2) CT (8) DE (3) FL (16) GA (7) IL (3) IN (4) KS (1) KY (5) LA (7) MA (5) MD (4) MI (8) MN (1) MO (6) MS (3) NC (6) NE (2)

	Antidiabetics (n=89)	Antidepressants (n=29)	Anticoagulants† (n=61)	Total number of reports by state
	TX (9) UT (1) VA (4)		TX (5) VA (2) WA (1)	NJ (2) NM (3) NV (2) NY (14) OH (8) OK (1) PA (6) RI (1) SC (1) TN (3) TX (18) UT (1) VA (7) WA (1)
*The reporter's state was not reported in 34 of 213 reports † These reports include NOAC discontinuation reports previously identified in the prior Congressional request				

APPENDIX A. LIMITATIONS

We did not have sufficient information to confirm the adverse events reported following drug discontinuation were related directly to the discontinuation (i.e., the event may have been related to underlying disease or other etiologies). Additional limitations of our assessment are consistent with those of spontaneously reported data and include underreporting, variable reporting quality, selective or delayed reporting, and the lack of event adjudication. Most reports did not provide sufficient information to determine if the advertisement the patient viewed was a legal advertisement (i.e., advertisements that advise consumers to contact a law firm for help) or an advertisement promoting the drug.

Identification of FAERS reports describing drug discontinuation following a legal advertisement requires a manual assessment of each report's narrative by specialized safety staff. Because the FDA has received over 1 million adverse event reports for the drug products requested, we used a search strategy that considered the feasibility of review in addition to specificity of terms. It is possible that there are additional relevant reports in FAERS; however, the number is likely small given the low yield from using the search terms that were determined to be more specific (i.e., we were able to determine a legal advertisement preceded a discontinuation in fewer than 2% of the 2,865 reports manually reviewed).

APPENDIX B. FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

The FDA Adverse Event Reporting System (FAERS) is a database that contains information on adverse event reports submitted to FDA. The database is designed to support the FDA's post-marketing safety surveillance program for drug and biologic products. The informatic structure of the database adheres to the international safety reporting

guidance issued by the International Conference on Harmonisation. Adverse events are coded to terms in the Medical Dictionary for Regulatory Activities (MedDRA) terminology. The suspect products are coded to valid tradenames or active ingredients in the FAERS Product Dictionary (FPD).

FAERS data have limitations. First, there is no certainty that the reported event was actually due to the product. FDA does not require that a causal relationship between a product and event be shown, and reports often do not contain enough detail to properly evaluate an event. Further, FDA does not receive reports for every adverse event or medication error that occurs with a product. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error in the U.S. population.

APPENDIX C. PRODUCT ACTIVE INGREDIENTS EVALUATED

Anticoagulants

Apixaban
Argatroban
Bivalirudin
Dabigatran
Dabigatran Etexilate
Dabigatran Etexilate Mesylate
Dalteparin
Dalteparin Sodium
Dextrose\Heparin
Dextrose\Heparin Sodium
Edoxaban Tosylate
Enoxaparin
Enoxaparin Sodium
Enoxaparin\Enoxaparin Sodium
Fondaparinux
Fondaparinux Sodium
Heparin Calcium
Heparin Sodium
Heparin Sodium\Sodium Chloride
Rivaroxaban
Warfarin
Warfarin Potassium
Warfarin Sodium

Antidepressants*

Agomelatine	Levomilnacipran Hydrochloride
Amitriptyline Hydrochloride	Fluoxetine Hydrochloride
Amitriptyline	Fluoxetine Hydrochloride\Olanzapine
Amitriptyline Hydrochloride\Chlordiazepoxide	Fluvoxamine
Amitriptyline Hydrochloride\Perphenazine	Fluvoxamine Maleate
Amitriptyline\Chlordiazepoxide	Imipramine
Amitriptyline\Perphenazine	Imipramine Hydrochloride
Amitriptylinoxide	Imipramine Pamoate
Amoxapine	Isocarboxazid

Clomipramine Hydrochloride	Levomilnacipran
Bupropion Hydrobromide	Sertraline Hydrochloride
Mirtazapine	Mianserin Hydrochloride
Nortriptyline Hydrochloride	Milnacipran
Vortioxetine Hydrobromide	Moclobemide
Bupropion Hydrochloride	Phenelzine Sulfate
Bupropion	Nefazodone
Citalopram Hydrobromide	Nefazodone Hydrochloride
Choline\Citalopram Hydrobromide	Norfluoxetine
Choline\Fluoxetine Hydrochloride	Nortriptyline
Escitalopram Oxalate	Opipramol
Citalopram Hydrochloride	Tranylcypromine Sulfate
Clomipramine	Paroxetine
Duloxetine Hydrochloride	Paroxetine Hydrochloride
Desipramine	Paroxetine Mesylate
Desipramine Hydrochloride	Phenelzine
Desvenlafaxine	Protriptyline
Desvenlafaxine Succinate	Protriptyline Hydrochloride
Trazodone Hydrochloride	Trimipramine Maleate
Doxepin	Tranylcypromine
Doxepin Hydrochloride	Trimipramine
Duloxetine	Vilazodone Hydrochloride
Reboxetine Mesylate	Vilazodone
Venlafaxine Hydrochloride	Viloxazine Hydrochloride
Selegiline	Vortioxetine
Olanzapine	Aripiprazole
Quetiapine	Quetiapine Fumarate

*List includes atypical antipsychotics with indications for major depressive disorder or depressive episodes associated with bipolar disorder.

Antidiabetic Products

Acarbose	Miglitol
Acetohexamide	Insulin Beef/Pork
Metformin Hydrochloride\Pioglitazone Hydrochloride	Insulin Pork\Insulin Purified Pork
Pioglitazone Hydrochloride	Insulin Beef
Insulin Human	Insulin Degludec
Lixisenatide	Insulin Degludec\Liraglutide
Insulin Lispro	Insulin Detemir
Metformin Hydrochloride	Insulin Glargine\Lixisenatide
Albiglutide	Insulin Nos
Aleglitazar	Ipragliflozin L-Proline
Alogliptin	Metformin Hydrochloride\Sitagliptin Phosphate
Alogliptin Benzoate\Metformin Hydrochloride	Sitagliptin Phosphate
Alogliptin Benzoate\Pioglitazone Hydrochloride	Linagliptin\Metformin Hydrochloride
Alogliptin Benzoate	Simvastatin\Sitagliptin Phosphate
Glimepiride	Metformin Hydrochloride\Saxagliptin Hydrochloride
Aminoglutethimide	Linagliptin
Insulin Glulisine	Liraglutide
Metformin Hydrochloride\Rosiglitazone Maleate	Phenformin
Glimepiride\Rosiglitazone Maleate	Metformin Hydrochloride\Saxagliptin
Rosiglitazone Maleate	Metformin Hydrochloride\Sitagliptin
Insulin Glargine	Metformin Hydrochloride\Vildagliptin
Buformin	Metformin\Nateglinide

Exenatide	Metformin\Sitagliptin
Canagliflozin	Metformin\Sitagliptin Phosphate
Canagliflozin\Metformin Hydrochloride	Metformin\Vildagliptin
Chlorpropamide	Mitiglinide
Clikstar	Nateglinide
Bromocriptine Mesylate	Omarigliptin
Dapagliflozin	Saxagliptin Hydrochloride
Dapagliflozin Propanediol	Tolbutamide
Dapagliflozin Propanediol\Metformin Hydrochloride	Tolbutamide Sodium
Phenformin Hydrochloride	Semaglutide
Glyburide	Pioglitazone
Diazoxide	Pramlintide Acetate
Glimepiride\Pioglitazone Hydrochloride	Metformin Hydrochloride\Repaglinide
Dulaglutide	Repaglinide
Empagliflozin	Dapagliflozin\Saxagliptin Hydrochloride
Empagliflozin\Linagliptin	Troglitazone
Empagliflozin\Metformin Hydrochloride	Rosiglitazone
Ertugliflozin	Insulin Aspart\Insulin Degludec
Insulin Aspart	Saxagliptin
Gliclazide	Ertugliflozin Pidolate\Metformin Hydrochloride
Glimepiride\Metformin	Sitagliptin
Glimepiride\Metformin\Voglibose	Ertugliflozin Pidolate
Glipizide	Ertugliflozin Pidolate\Sitagliptin Phosphate
Glipizide\Metformin Hydrochloride	Tofogliflozin
Glucagon Hydrochloride	Tolazamide
Glucagon	Vildagliptin
Glyburide\Metformin Hydrochloride	Voglibose
Glyburide\Metformin	

APPENDIX D. FAERS REPORT NUMBERS, FAERS VERSION NUMBERS, AND MANUFACTURER CONTROL NUMBERS

FAERS Report Number	FAERS Version Number	Manufacturer Control Number
3736010	1	Direct Report
4198147	1	US_0408104756
6031769	1	2006UW06965
6417804	2	US-ASTRAZENECA-2006UW27841
7285663	1	US-ELI_LILLY_AND_COMPANY-US201002003274
7548233	1	Direct Report
7591624	1	US-ASTRAZENECA-2007UW06152
7596548	1	US-ASTRAZENECA-2010SE12191
8292643	1	Direct Report
8391447	1	Direct Report
8525578	1	US-ELI_LILLY_AND_COMPANY-US201204002971
8612099	1	Direct Report
8737713	1	Direct Report
9355224	1	Direct Report
10438411	1	US-BRISTOL-MYERS SQUIBB COMPANY-20561585
10440114	1	US-BRISTOL-MYERS SQUIBB COMPANY-19413897
10724546	1	US-ROXANE LABORATORIES, INC.-2015-RO-00088RO
10932533	3	US-JNJFOC-20141117048
11217726	1	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-039970

11471156	2	US-ELI_LILLY_AND_COMPANY-US201201006154
11482290	2	US-ELI_LILLY_AND_COMPANY-US201204001760
11482915	2	US-ELI_LILLY_AND_COMPANY-US201201005763
11482946	1	US-ELI_LILLY_AND_COMPANY-US201203006763
11484972	1	US-ELI_LILLY_AND_COMPANY-US201209002142
11484997	1	US-ELI_LILLY_AND_COMPANY-US201209002314
11526390	1	US-ELI_LILLY_AND_COMPANY-US201308007727
11913338	1	Direct Report
12173859	1	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018740
12345530	1	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-034813
12825612	1	Direct Report
13137892	3	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004249
13236437	2	US-ELI_LILLY_AND_COMPANY-US201607008851
14068474	1	Direct Report
14272932	1	US-OTSUKA-2017_000941
14367487	1	Direct Report
14542611	1	US-OTSUKA-DJ201402892
12213379	1	Direct Report
12276324	2	US-JNJFOC-20160413109
12469243	1	US-JNJFOC-20160611604
12710873	1	US-JNJFOC-20160701093
12790435	1	US-ASTRAZENECA-2008BM13590
12806264	1	Direct Report
12895834	1	US-JNJFOC-20160919613
12895910	1	US-JNJFOC-20161018872
12895936	2	US-JNJFOC-20160825941
13126045	2	US-NOVOPROD-526549
13396469	2	US-JNJFOC-20170320626
14259180	1	US-JNJFOC-20171137763
14401939	2	US-JNJFOC-20180112851
14411195	1	US-JNJFOC-20171209155
14676965	1	US-JNJFOC-20180317158
14787166	1	US-JNJFOC-20180344964
14824272	1	US-JNJFOC-20180415523
14903393	1	US-SA-2017SA140425
14905167	1	US-SA-2017SA226282
15363996	1	US-JNJFOC-20180839992
14328553	1	US-JNJFOC-20171223814
14916889	2	US-JNJFOC-20180512844
15254679	1	US-SA-2018SA197774
15274154	6	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-04
3001064	3	001-0991-971226
3149837	2	001-0991-981893
3721643	3	2001020550-1
3948334	1	Direct Report
4174518	1	US-GLAXOSMITHKLINE-A0443057A
4174816	2	US-GLAXOSMITHKLINE-A0508206A
6323481	2	A0653178A
6367744	3	A0665821A
6463939	1	A0652185A
6708365	1	A0657632A
6708416	1	A0664903A
6834587	6	A0759186A

6867956	1	Direct Report
6959027	6	A0776641A
7009935	3	A0788113A
7022010	3	A0790450A
7023297	5	A0790820A
7036155	3	A0766619A
7060629	1	A0738269A
7068945	2	A0799508A
7071852	2	A0790458A
7138378	2	A0810009A
7138385	2	A0810019A
7453422	2	US-ELI_LILLY_AND_COMPANY-US201007000469
7542276	1	TPA2010A04259
7572725	1	A0878677A
7701908	3	A0898494A
7798772	1	US-BRISTOL-MYERS SQUIBB COMPANY-15512379
7906483	1	A0849012A
8096459	1	US-GLAXOSMITHKLINE-A0839780A
8115200	1	US-GLAXOSMITHKLINE-A0875011A
8172751	2	US-GLAXOSMITHKLINE-A0881162A
8226136	4	US-GLAXOSMITHKLINE-A0915676A
8276628	1	US-GLAXOSMITHKLINE-A0884665A
8276649	2	US-GLAXOSMITHKLINE-A0931090A
8319549	2	US-GLAXOSMITHKLINE-A0934674A
8329164	2	US-GLAXOSMITHKLINE-A0834452A
8342041	1	US-GLAXOSMITHKLINE-B0730664A
8389723	4	US-GLAXOSMITHKLINE-A0913489A
8422842	1	US-GLAXOSMITHKLINE-A0849012A
8578487	1	US-MERCK-1204USA01641
8603183	2	US-GLAXOSMITHKLINE-A0875872A
8628693	4	US-009507513-1204USA03840
8669083	2	US-009507513-1207USA001432
8694600	1	US-GLAXOSMITHKLINE-A0790237A
8718136	3	TPA2012A04831
8770067	3	US-009507513-1201USA03652
8843013	2	US-GLAXOSMITHKLINE-A0775980A
8917650	1	US-MERCK-1211USA006797
8932157	1	US-MERCK-1211USA011429
8952270	3	US-MERCK-1212USA000767
8973141	3	US-009507513-1212USA006360
9024483	1	US-009507513-1301USA006113
9179585	1	US-GLAXOSMITHKLINE-A0815636A
9208106	1	US-009507513-1304USA000794
9226388	1	US-009507513-1304USA003455
9270914	1	US-009507513-1305USA000575
9276335	1	US-GLAXOSMITHKLINE-A0757551A
9284558	4	US-009507513-1305USA003539
9303704	1	US-GLAXOSMITHKLINE-A0783333A
9400887	3	US-GLAXOSMITHKLINE-A1033009A
9414335	1	US-GLAXOSMITHKLINE-A0837513A
9692710	1	Direct Report
9711215	1	US-BRISTOL-MYERS SQUIBB COMPANY-18738260
9711370	2	US-BRISTOL-MYERS SQUIBB COMPANY-19217124

9722365	2	US-009507513-1311USA010382
9889829	3	US-009507513-1402USA004622
9901824	2	US-GLAXOSMITHKLINE-A1036071A
9924102	1	US-009507513-1402USA011448
9993649	1	US-009507513-1403USA002546
10025170	5	US-MERCK-1403USA009219
10385391	2	US-GLAXOSMITHKLINE-A0745296A
10396602	2	US-GLAXOSMITHKLINE-A0719198A
10483712	1	US-009507513-1409USA014646
10607903	2	US-BRISTOL-MYERS SQUIBB COMPANY-21459953
10630591	1	Direct Report
10651676	1	US-009507513-1412USA005621
10753969	1	Direct Report
11056904	3	US-JNJFOC-20150312002
11105649	1	US-009507513-1505USA002254
11282694	1	US-JNJFOC-20150708845
11330488	2	US-ASTRAZENECA-2015SE72777
11343992	1	US-JNJFOC-20150723003
11369993	1	US-JNJFOC-20150800398
11403154	1	Direct Report
11408168	1	US-NOVOPROD-440226
11757804	2	US-JNJFOC-20151115711
12127663	1	US-APOTEX-2015AP015388
13149457	2	US-JNJFOC-20170121089
13341774	1	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015047
13598486	1	US-JNJFOC-20170526534
13729666	1	US-JNJFOC-20170324930
13730853	6	US-JNJFOC-20170611527
11187200	1	US-JNJFOC-20150423971
11755434	1	US-JNJFOC-20151116924
12204585	2	US-JNJFOC-20160318682
10593492	1	US-JNJFOC-20141108462
11187588	1	US-JNJFOC-20150509080
11187491	2	US-JNJFOC-20150507305
11280888	1	US-JNJFOC-20150415479
11341055	2	US-JNJFOC-20150800157
9566607	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-29995BP
10955674	1	US-JNJFOC-20150311014
13016055	2	US-JNJFOC-20161115394
10305941	1	
10993284	2	US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019096
11058813	1	US-JNJFOC-20150416037
11062028	1	US-JNJFOC-20150418417
11086002	2	US-JNJFOC-20150414999
11496747	2	US-JNJFOC-20150809730
11539703	1	US-JNJFOC-20150913870
11705668	1	US-JNJFOC-20151103205
11834644	1	US-JNJFOC-20151202517
12659652	2	US-JNJFOC-20160810948
8812704	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2012-BP-23284BP
11085415	2	US-JNJFOC-20150318032
11340978	1	US-JNJFOC-20150719847
8546638	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2012-BP-09708BP

10892124	2	US-JNJFOC-20150217754
11033532	2	US-JNJFOC-20150217748
8783247	5	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2012-BP-22419BP
11040472	2	US-JNJFOC-20141101271
11132093	1	US-JNJFOC-20150511236
12085001	2	US-JNJFOC-20160211583
11130833	1	US-JNJFOC-20150510497
12344646	1	US-JNJFOC-20160408775
10962280	1	US-JNJFOC-20150319289
11721546	1	US-JNJFOC-20150926767
12130647	2	US-JNJFOC-20160118912
12924398	2	US-JNJFOC-20161105136
9027746	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2013-BI-01034BP
10276971	1	
11280456	1	US-JNJFOC-20150519088
10026037	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2014-BI-11494BP
11130816	1	US-JNJFOC-20150511383
11268573	1	US-JNJFOC-20150705153
11086143	2	US-JNJFOC-20150409895
12516417	1	US-JNJFOC-20160511307
12733128	2	US-JNJFOC-20160816773
11052156	1	US-JNJFOC-20150413672
12319086	2	US-JNJFOC-20160425330
10615875	3	US-JNJFOC-20141115825
10386783	8	US-JNJFOC-20140807384
8945760	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2012-BI-01856BP
9943111	1	US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2014-BI-08358BP
10843740	1	US-JNJFOC-20150210309
11280968	2	US-JNJFOC-20150710673
12273189	2	US-JNJFOC-20160411987
10551607	2	US-JNJFOC-20141016788
12344243	1	US-JNJFOC-20160324756
11084626	2	US-JNJFOC-20150311015
11096743	1	US-JNJFOC-20150500389
12651710	1	US-JNJFOC-20160807695